(S)-(-)-N-[2-(3-Hydroxy-1H-indol-3-yl)-methyl]-acetamide improved the therapeutic efficacy of anti-PD1 against osteosarcoma
Publication date: Available online 7 November 2018Source: Journal of Bone OncologyAuthor(s): Xinge Shi, Xiqing Li, Hongqiang Wang, Zhenghong Yu, Yu Zhu, Yanzheng GaoABSTRACTImpressive responses have been observed in patients with cancer treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies through disinhibiting the immune system. However, tumors possess complex immunosuppressive tumor microenvironment to present therapeutic obstacles and the response rates to immune checkpoint inhibition remain low. One significant barrier to the effic...
Source: Journal of Bone Oncology - November 23, 2018 Category: Cancer & Oncology Source Type: research
Clinical Epidemiology and Treatment Outcomes of Spindle Cell Non-Osteogenic Bone Sarcomas – a Nationwide Population-based Study
ConclusionWe confirm SCS as a rare high-grade bone sarcoma entity, mostly among elderly patients and with a poor overall outcome The combined treatment of surgery and chemotherapy is essential to achieve optimal long-term survival of SCS. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 21, 2018 Category: Cancer & Oncology Source Type: research
Metastatic bone disease: Pathogenesis and therapeutic options up-date on bone metastasis management
Publication date: Available online 6 November 2018Source: Journal of Bone OncologyAuthor(s): Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco SilvestrisAbstractBone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival.A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development o...
Source: Journal of Bone Oncology - November 15, 2018 Category: Cancer & Oncology Source Type: research
(S)-(-)-N-[2-(3-Hydroxy-2-oxo-2,3-dihydro-1H-indol-3-yl)-ethyl]-acetamide improved the therapeutic efficacy of anti-PD1 against osteosarcoma
Publication date: Available online 7 November 2018Source: Journal of Bone OncologyAuthor(s): Xinge Shi, Xiqing Li, Hongqiang Wang, Zhenghong Yu, Yu Zhu, Yanzheng Gao, Chunsheng WangABSTRACTImpressive responses have been observed in patients with cancer treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies through disinhibiting the immune system. However, tumors possess complex immunosuppressive tumor microenvironment to present therapeutic obstacles and the response rates to immune checkpoint inhibition remain low. One significant barr...
Source: Journal of Bone Oncology - November 11, 2018 Category: Cancer & Oncology Source Type: research
Metastatic bone disease: pathogenesis and therapeutic options
Publication date: Available online 6 November 2018Source: Journal of Bone OncologyAuthor(s): Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco SilvestrisAbstractBone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival.A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development o...
Source: Journal of Bone Oncology - November 7, 2018 Category: Cancer & Oncology Source Type: research
The Association between Adherence with Oral Bisphosphonates and the Risk of Breast Cancer in post-menopausal women.
ConclusionIn this study, we did not find a significant association between oral BP therapy for osteoporosis and the risk of breast cancer in postmenopausal women. The discrepancy between our results and the reports of such an association in observational studies might originate from an indication bias. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 7, 2018 Category: Cancer & Oncology Source Type: research
(S)-(-)-N-[2-(3-Hydroxy-2-oxo-2,3-dihydro-1H-indol-3-yl)-ethyl]-acetamide enhanced the efficacy of anti-PD1 against osteosarcoma cancer
Publication date: Available online 7 November 2018Source: Journal of Bone OncologyAuthor(s): Daokui Qu, Hongbing Wang, Qiuling Bi, Jiangli Xiu, Zhen Liu, Chunsheng WangAbstractImmunotherapies have demonstrated durable clinical responses in various cancers through disinhibiting the immune system, especially for the emergence of anti-programmed cell death protein 1/anti-programmed death-ligand 1 (anti-PD1/anti-PD-L1). However, multiple mechanisms of immune suppression exist in tumors. The recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment is one significant barrier to efficacy of anti-PD1...
Source: Journal of Bone Oncology - November 7, 2018 Category: Cancer & Oncology Source Type: research
Feasibility of Total En-Bloc Spondylectomy on L5 by a Posterior-Only Approach: an Autopsy Study
ConclusionsIf the patient has an anterior-posterior diameter of L5 vertebral body shorter than 34.96mm, it is possible that the vertebral body can be taken out during TES in a posterior-only approach. Prevention of nerve roots or blood vessels damages, and the obstruction caused by iliac wings are difficulties of this procedure yet not insurmountable. TES on L5 by a posterior-only approach might a possible alternative in treating diseases like L5 vertebral body tumors. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 6, 2018 Category: Cancer & Oncology Source Type: research
MTHFR variant is associated with high-dose methotrexate-induced toxicity in the Chinese osteosarcoma patients
ConclusionsVariant rs1801133 was confirmed to have remarkable influence on the MTX-induced toxicity. We recommend identification of the genotype of MTHFR variant prior to the application of high-dose MTX to OS patients, which could be an important predictor to screen severe toxicities and thus improve treatment outcomes. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 2, 2018 Category: Cancer & Oncology Source Type: research
Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients
ConclusionsWe constructed nomograms that accurately predict OS and CSS of high-grade osteosarcoma patients. The nomograms can be used for counseling patients and establishing risk stratification. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research
Chondrosarcoma transformation in hereditary multiple exostoses: a systematic review and clinical and cost-effectiveness of a proposed screening model
Publication date: Available online 4 October 2018Source: Journal of Bone OncologyAuthor(s): Li Fei, Clara Ngoh, Daniel E Porter (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 5, 2018 Category: Cancer & Oncology Source Type: research
Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer
ConclusionThe incidence of bone metastases was 3 – 7 % in patients with CRC, and it was not possible to detect an increase in incidence over time. The most well established risk factors for BM are rectal cancer, having lymph node invasion at surgery of primary tumor, and lung metastases at any time. Other risk factors such as RAS mutation status have been suggested but results are not conclusive. Survival ranges from 5 – 21 months after diagnosis of BM depending on cohort, with survival of about 8 months in unselected patients. Several variables have been suggested as potential prognostic markers but are all poorly inv...
Source: Journal of Bone Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).
ConclusionsDisease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up. The biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
ConclusionsThese exploratory analyses support use of everolimus plus exemestane for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, and add to the body of evidence suggesting a potentially favorable impact of everolimus on bone turnover.Trial registrationNCT01626222. Registered 22 June 2012, https://clinicaltrials.gov/ct2/show/NCT01626222 (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research
Development and validation of nomograms predicting overall and cancer-specific survival of high-grade osteosarcoma patients
Conclusions: We constructed nomograms that accurately predict OS and CSS of high-grade osteosarcoma patients. The nomograms can be used for counseling patients and establishing risk stratification. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research
